MAP - Market Access Podcast

By Dr. Stefan WalzerBusiness Science Medicine Health & Fitness

MAP - Market Access Podcast episodes

July 15, 2022 Switzerland is strong in many aspects, so also in its health care system, Dr. Peter Indra?
The Swiss healthcare system is rather complex but at the same time quite effective. High expenditures into health care corresponds with high life expectancy. However, what are the core processes in Switzerland with regards to health care delivery? What is the path towards innovation pricing and new price models? And what is the status quo on (health care) digitalization?

Dr. Stefan Walzer discusses with Dr. Peter Indra one of the core stakeholders in the Swiss system with a wide ranging experience in the board of the Swiss payer institution BAG, core insurance companies and federal political levels.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #switzerland
35 min
July 01, 2022 AMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?
What have been the main changes after 10 years of AMNOG for pharmaceutical companies? What have been the biggest successes within these years? For orphan drug the benefit evaluation process was eased in order to keep incentives high. Have price expectations been up met - by both sides? After 10 years of AMNOG first conclusions and recommendations for changes can be made.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #amnog
38 min
June 15, 2022 What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian?
Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does Israel do this?
Dr. Stefan Walzer and Mirel Stelian are discussing in depth, how the application and reimbursement process works and what options are available for companies who want to enter the Israeli market. If you want to understand the Israeli health care market and specifically the reimbursement process in Israel, you should not miss this episode.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #israel
34 min
June 01, 2022 Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graaff?
The market access process in the Netherlands can be very special, especially for medical devices. Besides standard reimbursement processes with evidence-based medicine assessments, there are also more pragmatic pathways available. How do these work and what needs to be considered before moving into the Dutch health care market? Listen to the insightful discussion of Dr. Stefan Walzer and the Dutch market access expert Ron de Graaff.
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy, visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #netherlands
35 min
May 15, 2022 The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?
Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with new processes is always how the rules are being interpreted and applied. So, how important are clinical studies and when are those required? What are the price levels and negotiations components of the process? Can companies with a successful track record in Germany also be successful in Belgium?
Dr. Stefan Walzer and the Belgian market access expert Katrien de Groote are discussing these and other aspects around digital healthcare in Belgium.
Don’t miss these insights on market access for digital products!
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #belgium
21 min
May 01, 2022 Is European market access really so difficult? Tell us the truth being successful in Europe, Esther Nzenza!
Europe is one continent, with one Union (plus the UK)… Health policy is still the responsibility of each individual country and hence there are still (at least) as many reimbursement pathways as countries. Planning for business success in health care is hence difficult? Not necessarily according to Dr. Stefan Walzer and Esther Nzenza. Both show up important topics and to dos in order to plan and execute successfully. As a summary, local access leaders have a critical role and (obviously) R&D, Medical Affairs, Commercial, Regularity, Supply Chain all need to have a common touchpoint within market access.
Don’t miss these insights on market access and European business strategy!
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #jointHTA
28 min
April 15, 2022 What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?
EU joint HTA will become reality in the next few years as communicated recently by the European Commission. However, applicability and implementation questions are still open such as timing, inclusion into national regulations and HTA processes in the EU member states. In Canada a similar process, including a single joint HTA process which is then being implemented in the respective provinces, has been introduced early 2000s. Core question remains what could be learned by European health care systems especially with respect to reimbursement and market access.
The dedicated debate is lead by Dr. Stefan Walzer who is discussing the potential learnings and take-aways with Gabriel Tremblay, a well-known Canadian Health Economic Expert. Don’t miss theses insights.
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #jointHTA
44 min
April 01, 2022Digital Health Care is already fully utilized in the US, isn’t it?
Dr. Stefan Walzer and Kate Claessens, the experienced consultant on healthcare in the US, are discussing the public acceptance as well as the various reimbursement pathways in the USA. What is the status of digital health care in the USA? How does reimbursement work for the different paths? What changes might we expect with the Biden administration? And what are the next steps to take?
In order to make it even more practical, Anna Forsythe the Managing Partner at Purple Squirrel Economics and expert in global product commercialization and strategic drug development, has joined the discussion in the second half of the discussion. Don't miss these insights as well.
The US market is for sure very interesting for digital healthcare products. This podcast episode will help you to get an idea of your next steps to enter this attractive market.
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website:
MArS🎙 https://marketaccess-pricingstrategy.de/en/map-podcast/
Apple 🍏 https://podcasts.apple.com/de/podcast/map-market-access-podcast/id1583167559
Spotify 🎧 https://open.spotify.com/show/7E8ZmM8oVVMCO6ewp4djiu?si=287017e1b3d54819
Amazon music 📶 https://music.amazon.com/podcasts/f16a1357-0bc6-43fa-9516-dc9b883dc883/map---market-access-podcast

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #usa #diga #digital
1 hr 2 min
March 15, 2022Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?
The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, what does the new innovation pathway means to the industry and health care availability? How easy is it really to negotiate a premium price? Listen to the discussions and explanations of Dr Stefan Walzer and his experts from Italy Prof. Dr. Stefano Capri and Dr. Entela Xoxi.
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website:
MArS🎙 https://marketaccess-pricingstrategy.de/en/map-podcast/
Apple 🍏 https://podcasts.apple.com/de/podcast/map-market-access-podcast/id1583167559
Spotify 🎧 https://open.spotify.com/show/7E8ZmM8oVVMCO6ewp4djiu?si=287017e1b3d54819
Amazon music 📶 https://music.amazon.com/podcasts/f16a1357-0bc6-43fa-9516-dc9b883dc883/map---market-access-podcast

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #italy
29 min
March 01, 2022What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?
The Austrian market access pathway in the outpatient setting is unique in its pragmatic approach with their box system.
The two experts on the Austrian market, Dr. Stefan Walzer and Dr. Anna Bucsics, discuss about the pathways in Asutria but also the similarities between Germany and the Austrian system. On top, the joint EU HTA approach will also be included in a scenario analysis in terms of implementation. Listen into this breakthrough discussions with a span between Austria, Germany the EU.
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website:
MArS🎙 https://marketaccess-pricingstrategy.de/en/map-podcast/
Apple 🍏 https://podcasts.apple.com/de/podcast/map-market-access-podcast/id1583167559
Spotify 🎧 https://open.spotify.com/show/7E8ZmM8oVVMCO6ewp4djiu?si=287017e1b3d54819
Amazon music 📶 https://music.amazon.com/podcasts/f16a1357-0bc6-43fa-9516-dc9b883dc883/map---market-access-podcast

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #austria
31 min

About MAP - Market Access Podcast

From the publisher's feed

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world.

MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.

The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves.

Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany).

Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.

Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.